Document:

Exhibit 10.3

 

INDEMNITY AGREEMENT

 

This INDEMNITY AGREEMENT, dated
as of February 4, 2022 (this “Agreement”) is made by and among RUMBLEON, INC., a Nevada corporation (“Parent
Indemnitor”), and RUMBLEON FINANCE, LLC, a Nevada limited liability company (“Company Indemnitor”, and
together with Parent Indemnitor, individually and collectively, jointly and severally, “Indemnitor”), in favor CREDIT
SUISSE AG, NEW YORK BRANCH, as administrative, payment and collateral agent for the Secured Parties (in such capacities, “Agent”).

 

W I T N E S S E T H:

 

WHEREAS, ROF SPV I,
LLC, a Delaware limited liability company (“Borrower”), has entered into that certain Loan and Security Agreement
of even date herewith (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Loan Agreement”;
capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to such terms in the Loan Agreement) with
the Agent and each of the financial institutions from time to time party thereto (each a “Lender” and collectively,
the “Lenders”), pursuant to which the Lenders have agreed to extend a revolving credit facility to Borrower, subject
to the terms and conditions set forth in the Loan Agreement;

 

WHEREAS, each Indemnitor,
directly or indirectly, owns 100% of the Equity Interests of Borrower and hereby acknowledges that it will benefit from the transactions
contemplated by the Loan Agreement; and

 

WHEREAS, Lenders are
unwilling to make the Loan unless Indemnitor unconditionally guarantees to Agent, for itself and for the benefit of the Lenders, the payment
and performance of the Guaranteed Obligations (as defined herein) on the terms set forth herein.

 

NOW, THEREFORE, in consideration
of the promises contained herein, and for good and valuable consideration, the sufficiency of which is hereby acknowledged, and to induce
the Lenders to enter into the Loan Agreement and to make the Loan to Borrower thereunder, the Indemnitor hereby agrees as follows:

 

SECTION 1. INDEMNITY.

 

(a) The
Indemnitor hereby unconditionally and irrevocably (i) guarantees to the Agent, for the ratable benefit of the Lenders, the prompt
and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of all of its respective Guaranteed
Obligations and (ii) agrees to pay all costs and expenses incurred by the Agent (including the fees and disbursements of counsel
and other professionals) in connection with (A) enforcing or defending Agent’s rights under or in respect of this Agreement
or (B) collecting the Guaranteed Obligations (including amounts that would become due but for the operation of the automatic stay
under Section 362(a) of the Bankruptcy Code, 11 U.S.C., 88 362(a)). Indemnitor hereby irrevocably and unconditionally covenants and
agrees that it is liable for the Guaranteed Obligations as a primary obligor.

 

(b) Subject
to Section 6, the Indemnitor hereby agrees, in furtherance of the foregoing and not in limitation of any other right which Agent
or any Lender may have at law or in equity against the Indemnitor by virtue hereof, that upon the failure of Borrower to pay any of the
Guaranteed Obligations when and as the same shall become due, whether at stated maturity, by required prepayment, declaration, acceleration,
demand or otherwise (including amounts that would become due but for the operation of the automatic stay under Section 362(a) of
the Bankruptcy Code, 11 U.S.C., 88 362(a)), the Indemnitor will upon demand pay, or cause to be paid, in cash, to Agent for the ratable
benefit of Lenders, an amount equal to the sum of the unpaid principal amount of all Guaranteed Obligations then due and payable as aforesaid,
any accrued and unpaid interest on such Guaranteed Obligations (including interest which, but for Borrower becoming the subject of a case
under the Bankruptcy Code, would have accrued on such Guaranteed Obligations, whether or not a claim is allowed against Borrower for such
interest in the related bankruptcy case) and all other Guaranteed Obligations then owed to Lenders as aforesaid. The Indemnitor hereby
agrees that all payments hereunder will be paid to the Agent without setoff, deduction or counterclaim at the office of the Agent located
at the address specified in Section 13 in U.S. dollars and in immediately available funds.

 

     

     

    

 

SECTION 2.
Definitions.

 

As used herein, the term “Guaranteed
Obligations” means:

 

(a) Any
actual loss, damage, settlement, judgment, cost, expense, liability, claim or other obligation incurred by Agent or any Lender (including,
without limitation, attorneys’ fees and costs incurred) arising out of or in connection with the following:

 

(i) any willful or
intentional misrepresentation or gross negligence by Borrower or any Indemnitor (each individually and collectively referred to
herein as a “Credit Party”) in connection with the Loan;

 

(ii) any
acts of fraud, misappropriation of funds or theft by any Credit Party;

 

(iii)  any
Change of Control not expressly approved in writing by Agent, at its sole option and in its sole discretion;

 

(iv)  any
sale, transfer, assignment or encumbrance of the Collateral in violation of the Loan Documents;

 

(v)  any
failure of Borrower to own the Receivables pledged as Collateral free and clear of all liens, security interests or encumbrances (other
than Permitted Liens);

 

(vi)  the
interference by Borrower (including its employees) or Indemnitor with Agent’s or any of its representatives’ or assigns’
access to or ability to access any location of Borrower and/or any Collateral during normal business hours and with prior advance written
notice;

 

(vii)  the
failure of Borrower to comply with the provisions of Section 6.13 of the Loan Agreement;

 

(viii)  the
assertion by any Credit Party of any clam, defense, or offset against Agent or any Lender that such Person has expressly waived or agreed
not to assert; and

 

(b)  The
entire amount of the Loan and all Obligations under the Loan Agreement following the occurrence of any of the following:

 

(i)  the
voluntary dissolution or liquidation of Borrower;

 

(ii)  the
substantive consolidation of Borrower with any Indemnitor under any proceeding under any Debtor Relief Law;

 

(iii)  any
Credit Party files a voluntary petition under the Bankruptcy Code or any other Debtor Relief Law, or consents to any such filing, or commences
a proceeding for the appointment of a receiver, trustee, liquidator or conservator of (A) any Credit Party, (B) the whole or any substantial
part of the Collateral, (C) a material portion of Borrower’s or Company Indemnitor’s other property or (D) the whole or substantial
part of Parent Indemnitor’s other property, except, in each case, to the extent, directly and indirectly, initiated or supported
by Agent, any Lender or any of their respective Affiliates;

 

(iv)  an
officer, director, representative of, or Person which controls, directly or indirectly, any Credit Party or an Affiliate of any of the
foregoing, files, or joins in the filing of, an involuntary petition against a Credit Party under the Bankruptcy Code or any Debtor Relief
Law, which is not dismissed within sixty (60) days of the date of its filing, or solicits or causes to be solicited petitioning creditors
for any involuntary petition against any Credit Party from any Person, except to the extent, directly and indirectly, initiated or supported
by Agent, any Lender or any of their respective Affiliates;

 

(v)  any
Credit Party files an answer consenting to or otherwise acquiescing in or joining in any involuntary petition filed against it, by any
other Person under the Bankruptcy Code or any other Debtor Relief Law, which is not dismissed within sixty (60) days of the date of its
filing, or solicits or causes to be solicited petitioning creditors for any involuntary petition from any Person, except to the extent,
directly or indirectly, initiated or supported by Agent, any Lender or any of their respective Affiliates; or

 

(vi)  in
any case or proceeding under the Bankruptcy Code or in any other judicial proceeding, any Credit Party makes application to a court to
declare that (A) all or any portion of the Lien of Agent or the obligations of Borrower to pay principal and interest as specified in
the Loan Documents be rescinded, set aside, or determined to be void or unenforceable or (B) any of the terms of any of the Loan Documents
be modified without Agent’s consent or the consent of each Person whose consent is required by the terms of such Loan Document.

 

    -2-

     

    

 

SECTION 3. Guaranty
Absolute. The Indemnitor guarantees that the Guaranteed Obligations will be paid strictly in accordance with the terms of this
Agreement. The Indemnitor agrees that this Agreement is a guaranty of payment and performance when due and not of collectability. This
Agreement is a primary obligation of the Indemnitor and not merely a contract of surety. The liability of the Indemnitor under this Agreement
shall be absolute, irrevocable and unconditional irrespective of:

 

(a)  any
lack of validity, regularity or enforceability of the Loan Agreement or any other Loan Document;

 

(b)  any
lack of validity, regularity or enforceability of this Agreement;

 

(c)  any
change in the time, manner or place of payment of, or in any other term of, all or any of the Obligations, or any other amendment or waiver
of or any consent to departure from the Loan Agreement or any other Loan Document;

 

(d)  any
exchange, release or non-perfection of any security interest in any collateral, or any release or amendment or waiver of or consent to
departure from any other guaranty, for all or any of the Obligations;

 

(e)  any
failure on the part of the Agent or any other Person to exercise, or any delay in exercising, any right under the Loan Agreement or any
other Loan Document; or

 

(f)  any
other circumstance which might otherwise constitute a defense available to, or a discharge of, Borrower, the Indemnitor or any other indemnitor
or guarantor with respect to the Guaranteed Obligations (including, without limitation, all defenses based on suretyship or impairment
of collateral, and all defenses that Borrower may assert to the repayment of the Guaranteed Obligations, including, without limitation,
failure of consideration, breach of warranty, payment, statute of frauds, bankruptcy, lack of legal capacity, statute of limitations,
lender liability, accord and satisfaction, and usury), this Agreement and the obligations of the Indemnitor under this Agreement.

 

The Indemnitor hereby agrees
that if Borrower or any other guarantor of all or a portion of the Guaranteed Obligations is the subject of a bankruptcy case under the
Bankruptcy Code, it will not assert the pendency of such case or any order entered therein as a defense to the timely payment of the Guaranteed
Obligations. The Indemnitor hereby waives notice of or proof of reliance by the Agent or any Lender upon this Agreement, and the Guaranteed
Obligations shall conclusively be deemed to have been created, contracted, incurred, renewed, extended, amended or reduced (as to Borrower
only) in reliance upon this Agreement.

 

SECTION 4. Interests.
The Indemnitor hereby acknowledges that certain of the rates of interest applicable to the Guaranteed Obligations shall be computed
on the basis of a year of 360 days, and paid for the actual number of days elapsed in accordance with Section 2.2(c) of the Loan
Agreement.

 

SECTION 5. Taxes.

 

(a)  The
Indemnitor shall make all payments required by it hereunder free and clear of and without deduction for any Taxes to the extent such payments
would be payable by Borrower free and clear of and without deduction for any Taxes in accordance with the Loan Agreement. If the Indemnitor
shall be required by Applicable Law to deduct or withhold any Taxes from or in respect of any sum payable by it hereunder to or for the
benefit of the Agent or any Lender, (i) if such Taxes would be payable by the Borrower in accordance with the Loan Agreement, then the
sum payable shall be increased as may be necessary so that after making all required deductions or withholdings of Taxes (including deductions
or withholdings of Taxes applicable to additional sums payable under Section 14.1 of the Loan Agreement) the Agent or such Lender
receives an amount equal to the sum it would have received had no such deductions or withholdings been made, (ii) the Indemnitor
shall make such deductions or withholdings and (iii) the Indemnitor shall pay the full amount so deducted or withheld to the relevant
taxation authority or other Governmental Authority in accordance with Applicable Law.

 

(b)  The
Indemnitor agrees to indemnify Agent for the full amount of Taxes or Other Taxes not deducted or withheld or not paid by the Indemnitor
to the extent required pursuant to Subsection 5(a) and any Taxes or Other Taxes imposed by any jurisdiction on the amounts
payable by the Indemnitor to the extent required pursuant to Subsection 5(a) and paid by any party, and any liability (including
penalties, interest and expenses) arising therefrom or with respect thereto, whether or not any such Taxes or Other Taxes were correctly
or legally asserted. Payment under this indemnification shall be made within fifteen (15) Business Days from the date the Agent makes
written demand therefor. A certificate as to the amount of such Taxes or Other Taxes and evidence of payment thereof submitted to the
Indemnitor by the Agent shall be prima facie evidence of the amount due from the Indemnitor to a party.

 

    -3-

     

    

 

(c)  The
Indemnitor shall furnish to the Agent the original or a certified copy of a receipt evidencing any payment of Taxes or Other Taxes made
by the Indemnitor as soon as such receipt becomes available, together with a certificate of an officer of the Indemnitor, which certificate
indicates the amount of Taxes or Other Taxes, as the case may be, deducted or withheld by the Indemnitor in respect of payments made hereunder.

 

(d)  Without
prejudice to the survival of any other agreement or obligation of the Indemnitor hereunder, the obligations of the Indemnitor under this
Section 5 shall survive the termination of this Agreement and the payment of the Guaranteed Obligations.

 

SECTION 6. Fraudulent
Conveyance. Notwithstanding any provision of this Agreement to the contrary, it is intended that this Agreement, and any Liens
granted by Company Indemnitor to secure the obligations and liabilities arising pursuant to this Agreement, not constitute a “Fraudulent
Conveyance” (as defined below). Consequently, the Indemnitor agrees that if this Agreement, or any Liens securing the obligations
and liabilities of the Company Indemnitor arising pursuant to this Agreement, would, but for the application of this sentence, constitute
a Fraudulent Conveyance, this Agreement and each such Lien shall be valid and enforceable only to the maximum extent that would not cause
this Agreement or such Lien to constitute a Fraudulent Conveyance, and this Agreement shall automatically be deemed to have been amended
accordingly at all relevant times. For purposes hereof, “Fraudulent Conveyance” means a fraudulent conveyance or fraudulent
transfer under Section 548 of the Bankruptcy Code or a fraudulent conveyance or fraudulent transfer under the provisions of any applicable
fraudulent conveyance or fraudulent transfer law or similar law of any state of the United States, as in effect from time to time.

 

SECTION 7. Waiver.
The Indemnitor hereby waives, for the benefit of Agent and Lenders (a) any right to require any Agent or any Lender, as a condition of
payment or performance by the Indemnitor, to (i) proceed against Borrower, any other guarantor of the Guaranteed Obligations or any other
Person, (ii) proceed against or exhaust any security held from Borrower, any such other guarantor or any other Person, (iii) proceed against
or have resort to any balance of any deposit account or credit on the books of Agent or any Lender in favor of Borrower or any other Person
or (iv) pursue any other remedy in the power of Agent or any Lender whatsoever; (b) any defense arising by reason of the incapacity, lack
of authority or any disability or other defense of Borrower or any other guarantor or indemnitor, including any defense based on or arising
out of the lack of validity or the unenforceability of the Guaranteed Obligations or any agreement or instrument relating thereto or by
reason of the cessation of the liability of Borrower or any other guarantor or indemnitor from any cause other than payment in full of
the Guaranteed Obligations; (c) any defense based upon any statute or rule of law which provides that the obligation of a surety must
be neither larger in amount nor in other respects more burdensome than that of the principal; (d) any defense based upon Agent or any
Lender’s errors or omissions in the administration of the Guaranteed Obligations, except errors and omissions resulting from Agent
or any Lender’s gross negligence or willful misconduct; (e)(i) any principles or provisions of law, statutory or otherwise, which
are or might be in conflict with the terms hereof and any legal or equitable discharge of the Indemnitor’s obligations hereunder,
(ii) the benefit of any statute of limitations affecting the Indemnitor’s liability hereunder or the enforcement hereof, (iii) any
rights to set-offs, recoupments and counterclaims, and (iv) promptness, diligence and any requirement that any Lender protect, secure,
perfect or insure any security interest or lien or any property subject thereto; (f) notices, demands, presentments, protests, notices
of protest, notices of dishonor and notices of any action or inaction, including acceptance hereof, notices of default hereunder, or any
other Loan Document, notices of any renewal, extension or modification of the Guaranteed Obligations or any Loan Document, notices of
any extension of credit to Borrower and notices of any of the matters referred to in Section 3 and any right to consent to
any thereof; and (g) any defenses (other than payment) or benefits that may be derived from or afforded by law which limit the liability
of or exonerate guarantors or sureties, or which may conflict with the terms hereof.

 

SECTION 8. Subrogation;
Subordination. The Indemnitor hereby agrees that it will not exercise or assert any rights or claims which it may acquire against
Borrower or any other guarantor of all or part of the Guaranteed Obligations that arise from the existence, payment, performance or enforcement
of its obligations hereunder (including, without limitation, any rights or claims of subrogation, reimbursement or contribution), until
the indefeasible payment in full in cash of its respective Guaranteed Obligations. If any amount shall be paid to the Indemnitor in violation
of the immediately preceding sentence, such amount shall be held in trust for the benefit of the Agent and shall forthwith be paid to
the Agent for the ratable benefit of the Lenders to be credited and applied against the Guaranteed Obligations and all other amounts payable
under Section 1(a)(ii), whether matured or unmatured, in such order as the Agent may determine. Any Indebtedness of Borrower or
Indemnitor now or hereafter held by any Indemnitor (the “Obligee Indemnitor”) is hereby subordinated in right of payment
to the Guaranteed Obligations, and any such indebtedness collected or received by the Obligee Indemnitor after an Event of Default has
occurred and is continuing shall be held in trust for Agent on behalf of Lenders and shall forthwith be paid over to Agent for the benefit
of Lenders to be credited and applied against the Guaranteed Obligations but without affecting, impairing or limiting in any manner the
liability of the Obligee Indemnitor under any other provision hereof.

 

    -4-

     

    

 

SECTION 9. Representations
and Warranties.

 

(a)  The
Indemnitor has, independently and without reliance upon the Agent or any Lender and based on such documents and information as it has
deemed appropriate, made its own credit analysis and decision to enter into this Agreement.

 

(b)  In
addition to and without limitation of any of the foregoing, this Agreement shall be deemed to be a Loan Document.

 

SECTION 10. Distributions.
Except as otherwise agreed to by Agent in its sole discretion, Company Indemnitor shall not (a) declare, pay or make any dividend
or distribution on any Equity Interests or other securities or ownership interests, (b) apply any of its funds, property or assets
to the acquisition, redemption or other retirement of any Equity Interests or other securities or interests or of any options to purchase
or acquire any of the foregoing, (c) otherwise make any payments, dividends or distributions to any member, manager, managing member,
stockholder, director or other equity owner in such Person’s capacity as such, (d) make any payment of any management, service
or related or similar fee to any Affiliate or holder of Equity Interests or (e) issue, sell or create any Equity Interests; provided,
however, that so long as no Event of Default or Early Wind-Down Trigger Event has occurred and is continuing, or would be caused
by such dividend or distribution, Company Indemnitor may make distributions and/or dividends.

 

SECTION 11. Right of
Setoff. In addition to and not in limitation of all rights of offset that the Agent and each Lender or any of their respective
Affiliates may have under Applicable Law, and whether or not the Agent or any Lender has made any demand or the obligations of the Indemnitor
have matured, the Agent and each Lender and their respective Affiliates shall have the right to set off and apply any and all deposits
(general or special, time or demand, provisional or final, or any other type) at any time held and any other Indebtedness at any time
owing by the Agent or any Lender or any of their respective Affiliates to or for the credit or the account of the Indemnitor against any
and all of the Guaranteed Obligations. If the Agent or any Lender exercises any of its rights under this Section 11, the Agent
or such Lender, as the case may be, shall provide notice to the Indemnitor of such exercise, provided that the failure to give such notice
shall not affect the validity of the exercise of such rights.

 

SECTION 12. Survival
of Provisions. All payment obligations, covenants, representations, warranties and waivers and indemnities made by the Indemnitor
under this Agreement shall survive the execution, delivery, and termination of this Agreement until all Obligations are performed in full
and indefeasibly paid in full in cash and the Loan Documents are terminated.

 

SECTION 13. Notices.
All notices and other communications hereunder shall be in writing and sent by certified or registered mail, return receipt requested,
by overnight delivery service, with all charges prepaid, by hand delivery, or by telecopier followed by a hard copy sent by regular mail,
if to the Agent, then to Credit Suisse AG, New York Branch, 11 Madison Avenue, 4th Floor, New York, NY 10010, E-mail: kenneth.aiani@credit-suisse.com,
Attention: Ken Aiani, with a copy to Holland & Knight LLP, 200 Crescent, 16th Floor, Dallas, Texas 75201, E-mail: stephen.ratliff@hklaw.com,
Attention: Stephen Ratliff, Esq., and if to Indemnitor, then to RumbleOn Finance, LLC, 1160 North Town Center Drive, Suite 130, Las Vegas,
NV 89144, Email: scott@rumbleon.com, Attention: Scott Raymer and to RumbleOn, Inc., 901 W. Walnut Hill Ln., Irving, TX 75038, Email: paul.jones@rumbleon.com
Attention: Paul Jones, or in each case, to such other address as any Indemnitor or the Agent may specify to the other party in the manner
required hereunder. All such notices and correspondence shall be deemed given (i) if sent by certified or registered mail, three
(3) Business Days after being postmarked, (ii) if sent by overnight delivery service or by hand delivery, when received at the above
stated addresses or when delivery is refused, (iii) if sent by telecopier transmission, when such transmission is confirmed and (iv)
if sent by Electronic Transmission, upon telephone or further electronic communication from the recipient acknowledging receipt.

 

SECTION 14. Amendments,
Waivers and Consents. No amendment or waiver of any provision of this Agreement, or consent to any departure by the Indemnitor
therefrom, shall in any event be effective unless the same shall be in writing and signed by the Agent and, in the case of an amendment,
the Indemnitor, and then such amendment, waiver or consent shall be effective only in the specific instance and for the specific purpose
for which given.

    -5-

     

    

 

SECTION 15. Delays;
Partial Exercise of Remedies. No delay or omission of the Agent to exercise any right or remedy hereunder shall impair any such
right or operate as a waiver thereof. No single or partial exercise by the Agent of any right or remedy shall preclude any other or further
exercise thereof, or preclude any other right or remedy.

 

SECTION 16. Severability.
In case any provision in or obligation under this Agreement shall be invalid, illegal or unenforceable in any jurisdiction, the validity,
legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction,
shall not in any way be affected or impaired thereby.

 

SECTION 17. Interpretation.
To the extent a term or provision of this Agreement conflicts with the Loan Agreement and is not addressed herein with more specificity,
the Loan Agreement shall control with respect to the subject matter of such term or provision.

 

SECTION 18. Continuing
Guaranty; Assignments of Guaranteed Debt. This Agreement is a continuing guaranty and shall (a) remain in full force and
effect until released or terminated in accordance herewith, (b) be binding upon the Indemnitor and its successors and assigns, and
(c) inure, together with the rights and remedies of the Agent hereunder, to its own benefit and to its successors and assigns. Without
limiting the generality of the foregoing clause (c), the Agent may, in accordance with the terms of the Loan Agreement, assign or otherwise
transfer all or any portion of its rights and obligations under the Loan Agreement to any successor agent, and such successor agent shall
thereupon become vested with all the benefits in respect hereof granted to the Agent herein or otherwise, in each case as provided in
the Loan Agreement.

 

SECTION 19. Reinstatement.
To the extent permitted by law, this Agreement shall continue to be effective or be reinstated if at any time any amount received by the
Agent or any Lender in respect of the Obligations is rescinded or must otherwise be restored or returned by the Agent or such Lender upon
the occurrence or during the pendency of any bankruptcy, reorganization or other similar proceeding applicable to the Indemnitor, or upon
or during the occurrence of any dissolution, liquidation, provisional liquidation or winding up of the Indemnitor, all as though such
amount had not been received.

 

SECTION 20. Bankruptcy,
etc.

 

(a)  The
obligations of the Indemnitor hereunder shall not be reduced, limited, impaired, discharged, deferred, suspended or terminated by any
case or proceeding, voluntary or involuntary, involving the bankruptcy, insolvency, receivership, reorganization, winding-up, liquidation,
provisional liquidation or arrangement of Borrower or any other guarantor or indemnitor or by any defense which Borrower or any other
guarantor or indemnitor may have by reason of the order, decree or decision of any court or administrative body resulting from any such
proceeding.

 

(b)  The
Indemnitor acknowledges and agrees that any interest on any portion of the Guaranteed Obligations which accrues after the commencement
of any case or proceeding referred to in clause (a) above (or, if interest on any portion of the Guaranteed Obligations ceases to
accrue by operation of law by reason of the commencement of such case or proceeding, such interest as would have accrued on such portion
of the Guaranteed Obligations if such case or proceeding had not been commenced) shall be included in the Guaranteed Obligations because
it is the intention of the Indemnitor and Lenders that the Guaranteed Obligations which are guaranteed by the Indemnitor pursuant hereto
should be determined without regard to any rule of law or order which may relieve Borrower of any portion of such Guaranteed Obligations.
The Indemnitor will permit any trustee in bankruptcy, receiver, debtor in possession, assignee for the benefit of creditors or similar
person to pay Agent, or allow the claim of Agent in respect of, any such interest accruing after the date on which such case or proceeding
is commenced.

 

SECTION 21. Financial
Condition of Borrower. Any Advance may be made to Borrower or continued from time to time, without notice to or authorization
from any Indemnitor regardless of the financial or other condition of Borrower at the time of any such grant or continuation. Neither
Agent nor any Lender shall have any obligation to disclose or discuss with any Indemnitor its assessment, or any Indemnitor’s assessment,
of the financial condition of Borrower. The Indemnitor has adequate means to obtain information from Borrower on a continuing basis concerning
the financial condition of Borrower and its ability to perform its obligations under the Loan Documents, and the Indemnitor assumes the
responsibility for being and keeping informed of the financial condition of Borrower and of all circumstances bearing upon the risk of
nonpayment of the Guaranteed Obligations. The Indemnitor hereby waives and relinquishes any duty on the part of Agent or any Lender to
disclose any matter, fact or thing relating to the business, operations or conditions of Borrower now known or hereafter known by Agent
or any Lender.

 

    -6-

     

    

 

SECTION 22. Entire
Agreement; Successors and Assigns; Joint and Several. This Agreement constitutes the entire agreement between the parties hereto,
supersedes any prior written and verbal agreements between them, and shall bind and benefit the parties hereto and their respective successors
and permitted assigns. If Indemnitor consists of more than one person or party, the obligations and liabilities of each such person or
party shall be joint and several.

 

SECTION 23. GOVERNING
LAW. THE VALIDITY, INTERPRETATION AND ENFORCEMENT OF THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS AND ANY DISPUTE ARISING OUT OF
OR IN CONNECTION WITH THIS AGREEMENT OR ANY OF THE OTHER LOAN DOCUMENTS, WHETHER SOUNDING IN CONTRACT, TORT, EQUITY OR OTHERWISE, SHALL
BE GOVERNED BY THE INTERNAL LAWS (AS OPPOSED TO THE CONFLICTS OF LAW PROVISIONS OTHER THAN SECTION 5-1401 AND 5-1402 OF THE NEW YORK GENERAL
OBLIGATIONS LAW) AND DECISIONS OF THE STATE OF NEW YORK.

 

SECTION 24. SUBMISSION
TO JURISDICTION. ALL DISPUTES BETWEEN OR AMONG THE INDEMNITOR, AGENT AND THE LENDERS, WHETHER SOUNDING IN CONTRACT, TORT, EQUITY
OR OTHERWISE, SHALL BE RESOLVED ONLY BY STATE AND FEDERAL COURTS LOCATED IN NEW YORK, NEW YORK, AND THE COURTS TO WHICH AN APPEAL THEREFROM
MAY BE TAKEN; PROVIDED, HOWEVER, THAT THE AGENT SHALL HAVE THE RIGHT, TO THE EXTENT PERMITTED BY APPLICABLE LAW, TO PROCEED AGAINST THE
INDEMNITOR OR ITS PROPERTY IN (A) ANY COURTS OF COMPETENT JURISDICTION AND VENUE AND (B) ANY LOCATION SELECTED BY THE AGENT TO ENABLE
THE AGENT TO REALIZE ON SUCH PROPERTY, OR TO ENFORCE A JUDGMENT OR OTHER COURT ORDER IN FAVOR OF THE AGENT. THE INDEMNITOR AGREES THAT
IT WILL NOT ASSERT ANY PERMISSIVE (AS OPPOSED TO MANDATORY) COUNTERCLAIMS, SETOFFS OR CROSS-CLAIMS IN ANY PROCEEDING BROUGHT BY THE AGENT.
THE INDEMNITOR WAIVES ANY OBJECTION THAT IT MAY HAVE TO THE LOCATION OF THE COURT IN WHICH THE AGENT HAS COMMENCED A PROCEEDING, INCLUDING,
WITHOUT LIMITATION, ANY OBJECTION TO THE LAYING OF VENUE OR BASED ON FORUM NON CONVENIENS. BY EXECUTION AND DELIVERY OF EACH LOAN DOCUMENT
TO WHICH IT IS A PARTY, THE INDEMNITOR (i) ACCEPTS THE NON-EXCLUSIVE JURISDICTION OF THE AFORESAID COURTS AND IRREVOCABLY AGREES TO BE
BOUND BY ANY JUDGMENT RENDERED THEREBY, (ii) WAIVES PERSONAL SERVICE OF PROCESS, AND (iii) AGREES THAT SERVICE OF PROCESS UPON IT MAY
BE MADE BY CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED, PURSUANT TO SECTION 13.

 

SECTION 25. JURY TRIAL.
THE INDEMNITOR (AND BY ITS RECEIPT HEREOF, THE AGENT) HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY LAW ANY RIGHT TO A TRIAL BY JURY
IN ANY ACTION OR PROCEEDING BASED UPON, ARISING OUT OF, OR IN ANY WAY RELATING TO (I) THIS AGREEMENT OR (II) ANY CONDUCT, ACTS
OR OMISSIONS OF THE INDEMNITOR, THE AGENT, ANY LENDER OR ANY OF THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES, AGENTS, ATTORNEYS OR
OTHER AFFILIATES, IN EACH CASE WHETHER SOUNDING IN CONTRACT, TORT, EQUITY OR OTHERWISE.

 

SECTION 26. LIMITATION
OF LIABILITY. NEITHER THE AGENT NOR ANY LENDER SHALL HAVE ANY LIABILITY TO THE INDEMNITOR (WHETHER SOUNDING IN TORT, CONTRACT,
OR OTHERWISE) FOR LOSSES SUFFERED BY THE INDEMNITOR IN CONNECTION WITH, ARISING OUT OF, OR IN ANY WAY RELATED TO THE TRANSACTIONS OR RELATIONSHIPS
CONTEMPLATED BY THIS AGREEMENT, OR ANY ACT, OMISSION OR EVENT OCCURRING IN CONNECTION THEREWITH, UNLESS IT IS DETERMINED BY A FINAL AND
NONAPPEALABLE JUDGMENT OR COURT ORDER BINDING ON THE AGENT OR SUCH LENDER THAT THE LOSSES WERE THE RESULT OF ACTS OR OMISSIONS CONSTITUTING
GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF THE AGENT OR SUCH LENDER. THE INDEMNITOR HEREBY WAIVES ALL FUTURE CLAIMS AGAINST THE AGENT AND
EACH LENDER FOR SPECIAL, INDIRECT, CONSEQUENTIAL OR PUNITIVE DAMAGES.

 

SECTION 27. Counterparts;
Facsimile Signatures. This Agreement and any waiver or amendment hereto may be executed in counterparts and by the parties hereto
in separate counterparts, each of which when so executed and delivered shall be an original, but all of which shall together constitute
one and the same instrument. This Agreement may be executed and delivered by telecopier, facsimile transmission or Electronic Transmission
all with the same force and effect as if the same was a fully executed and delivered original manual counterpart. Delivery of an executed
signature page of this Agreement by telecopier, facsimile transmission or Electronic Transmission shall be as effective as delivery of
a manually executed counterpart hereof.

 

[Signature Page Follows]

 

    -7-

     

    

 

IN WITNESS WHEREOF, the
Indemnitor has caused this Agreement to be executed by its proper and duly authorized officer as of the date first set forth above.

 

	 	RUMBLEON, INC., 
	 	a Nevada corporation 
	 	 	 
	 	By:  	/s/ Marshall Chesrown
	 	Name:  	Marshall Chesrown
	 	Title:	Chairman and Chief Executive Officer
	 	 	 
	 	RUMBLEON FINANCE, LLC, 
	 	a Nevada limited liability company 
	 	 	 
	 	By: 	/s/ Scott Raymer
	 	Name:	Scott Raymer
	 	Title:	President

 

[Signature Page]

Indemnity AgreementDocument

Exhibit 10.14.4

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED.

FOURTH AMENDMENT TO AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT
THIS FOURTH AMENDMENT TO AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT (this “Fourth Amendment”), dated as of October 6, 2021 (the “Execution Date”) and effective as of September 30, 2021 (the “Effective Date”), is by and between Sanofi Biotechnology SAS, a sociéte par actions simplifiée, organized under the laws of France, as successor in interest to Aventis Pharmaceuticals Inc., having a principal place of business at 54, rue La Boétie, 75008 Paris, France (“Sanofi”), Sanofi, a société anonyme organized under the laws of the French Republic with its principal headquarters at 54, rue La Boétie, 75008 Paris, France (“Sanofi Parent”), and Regeneron Pharmaceuticals, Inc., a corporation organized under the laws of the state of New York and having a principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591 (“Regeneron”) (with each of Sanofi and Regeneron being sometimes referred to herein individually as a “Party” and collectively as the “Parties”). 
 RECITALS
WHEREAS, Regeneron, Sanofi and Sanofi Parent are parties to that certain Amended and Restated License and Collaboration Agreement dated as of November 10, 2009, as amended as of May 1, 2013, July 1, 2015, and April 5, 2020 (the “LCA”) for the Development, Manufacture and Commercialization of Licensed Products (as such terms are defined therein); and
WHEREAS, the Parties desire to amend the LCA to set forth certain terms and conditions regarding the Co-Commercialization by the Parties of the Licensed Product known as dupilumab (“Dupilumab”).
NOW, THEREFORE, in consideration of the following mutual covenants contained herein, and for other good and valuable consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
AGREEMENT
1.Definitions.
1.1.All capitalized terms used in this Fourth Amendment which are not otherwise defined herein shall have the meanings ascribed to them in the LCA.  
1.2.The definition of “Commercial Overhead Charge” in Section 1.17 of the LCA is hereby amended by deleting the last sentence of such definition and replacing it with the following: “For the avoidance of doubt, ‘Commercial Overhead Charge’ shall not include any amounts otherwise included in Shared Commercial Expenses (unless included solely pursuant to clause (i) thereof) or Other Shared Expenses.”

2.Acknowledgements and Agreements with respect to Dupilumab.  Solely with respect to Dupilumab, the Parties acknowledge and agree as follows:
2.1.    Dupilumab Budget.  The 2021 Global Commercialization Budget and Country/Region Commercialization Budgets for Dupilumab, which implement the terms of this Fourth Amendment for 2021, are attached as Schedule A to the side letter dated as of the date hereof and by and among the same Parties (the “Side Letter”) (collectively, the “2021 Budgets”).
2.2.    Dupilumab – Rest of World.  
(a)Dupilumab [* * *].  The Parties agree that the [* * *], as presented to the JSC at the [* * *] JSC meeting, are adopted and approved, and  included  in the 2021 Global Commercialization Plan and the applicable Country/Region Commercialization Plan, each including the corresponding budget,  reflected on Schedule A to the Side Letter.
(b)Rest of World Commercial Overhead FTEs for Dupilumab.
(c)For so long as each of Germany, the United Kingdom, the Netherlands, and Canada (collectively, the “Current Co-Commercialization Countries”) is a Co-Commercialization Country for Dupilumab, Regeneron will be entitled to [* * *] as follows: (i) in Germany, [* * *]; (ii) in the United Kingdom, [* * *]; (iii) in the Netherlands, [* * *]; and (iv) in Canada, [* * *].  In the event that Regeneron exercises its right to cease Co-Commercializing Dupilumab in a Current Co-Commercialization Country pursuant to Section 6.5(c) of the LCA, Regeneron’s Commercial Overhead FTEs for such Current Co-Commercialization Country will be eliminated accordingly.  “Commercial Overhead FTEs” means, with respect to Regeneron for Rest of World Co-Commercialization Countries, [* * *].  
(i)In addition to the Commercial Overhead FTEs in the Current Co-Commercialization Countries, the Parties acknowledge and agree that [* * *] (“Dupilumab Global HQ FTEs”) [* * *].  For further clarity, Dupilumab Global HQ FTEs and Commercial Overhead FTEs may be located in any country, including any Co-Commercialization Country.   
(ii)In any Rest of World Co-Commercialization Country for Dupilumab other than (1) the Current Co-Commercialization Countries and (2) any Sales Force Intensive Country (such countries, “Other Co-Commercialization Countries”), [* * *].  In any Rest of World Co-Commercialization Country for Dupilumab with [* * *] (such countries, “Sales Force Intensive Countries”), [* * *].
(iii)With respect to any Rest of World Co-Commercialization Country for Dupilumab, in accordance with an approved Country/Region Commercialization Plan and beginning no earlier than [* * *], Regeneron may start [* * *].  For the avoidance of doubt, each such FTE is to be engaged in preparations for Co-Commercialization at the time Regeneron includes such costs as a Commercial Overhead Charge.
(iv)The number of Commercial Overhead FTEs allocated [* * *] for (x) Current Co-Commercialization Countries pursuant to clause (i) above, (y) Other Co-Commercialization Countries pursuant to clause (iii) above, and (z) Sales Force Intensive Countries pursuant to clause (iii) above, shall be referred to as the “Commercial Overhead Allocation”.
2

(d)Rest of World Sales Force FTEs for Dupilumab.
(i)For so long as any of Germany, the United Kingdom, the Netherlands, and Canada is a Co-Commercialization Country for Dupilumab, Regeneron’s Sales Force FTEs in such country shall be [* * *], unless the Parties agree otherwise; provided that, for the 2021 Budgets, such Regeneron Sales Force FTEs in each Current Co-Commercialization Country shall be as follows, unless the Parties agree otherwise: (i) in Germany, [* * *]; (ii) in the United Kingdom, [* * *]; (iii) in the Netherlands, [* * *]; and (iv) in Canada, [* * *].  
(ii)In accordance with an approved Country/Region Commercialization Plan, [* * *] shall be allocated [* * *].  Such allocation of Out-of-Pocket Costs shall be referred to as the “ROW OOP Allocation”.
(iii)With respect to any Rest of World Co-Commercialization Country for Dupilumab, in accordance with an approved Country/Region Commercialization Plan and beginning no earlier [* * *], Regeneron may start [* * *]. For the avoidance of doubt, each such FTE is to be engaged in preparations for Co-Commercialization at the time Regeneron includes such costs as a Shared Commercial Expense.
(iv)The definition of “Sale Force Cost” in Section 1.108 of the  LCA is hereby amended such that, effective as of the Co-Commercialization Effective Date, [* * *].  Such method of calculating the Sales Force Cost shall be referred to as the “Co-Co Sales Force Cost”.  The “Co-Commercialization Effective Date” means the date of commencement of Co-Commercialization of Dupilumab in such Co-Commercialization Country as indicated in the Co-Commercialization notice provided to Sanofi from Regeneron pursuant to Section 6.5(a) of the LCA, unless otherwise agreed by the Parties; provided that, for clarity, such date shall be [* * *] in the case of any Current Co-Commercialization Country, unless otherwise agreed by the Parties.
(v)The number of Sales Force FTEs allocated [* * *] for Current Co-Commercialization Countries in clause (i) above shall be referred to as the “REGN Sales Force Allocation”.
(e)The Commercial Overhead Allocation, REGN Sales Force Allocation, ROW OOP Allocation, and Co-Co Sales Force Cost are reflected in the 2021 Budgets and [* * *].
(f)Commercial Plans and Budgets.  In accordance with the terms of the LCA, on an annual basis, (a) the Global Commercialization Plan (including the corresponding Global Commercialization Budget) for Dupilumab may be updated jointly by the Parties via the JCC and approved by the JSC, and (b) each Country/Region Commercialization Plan (including the corresponding Country/Region Commercialization Budget) for Dupilumab may be updated jointly by the Parties via the applicable Country/Region Commercialization Committee and approved by the JCC; provided that such Plans and budgets shall be consistent with the Commercial Overhead Allocation, REGN Sales Force Allocation, ROW OOP Allocation, Co-Co Sales Force Cost, and Global HQ FTE Allocation. 
2.3.    Dupilumab – United States.
(a)The United States Country/Region Commercialization Budget for Dupilumab (the “US Budget”) and the portions of the Global Commercialization Budget for 
3

Dupilumab covering the United States are reflected in the 2021 Budgets attached as Schedule A to the Side Letter, and detailed in Schedule B attached to the Side Letter.  FTEs for Commercialization of Dupilumab in the United States [* * *] shall be allocated as follows: (A) the aggregate number of FTEs supporting Dupilumab in the United States consisting [* * *] shall be allocated [* * *], and (B) US Commercial Overhead FTEs shall be allocated [* * *] (such ratios, collectively, as reflected in the updated 2021 US Budget, the “US FTE Allocation”).  “US Commercial Overhead FTEs” means those [* * *].  
(b)In addition to the US Commercial Overhead FTEs in the United States, the Parties acknowledge and agree that [* * *].        
(c)Out-of-Pocket Costs for Commercialization of Dupilumab in the United States [* * *] shall be allocated [* * *].  Such ratio shall be referred to as the “US OOP Allocation”.  The Parties hereby adopt and approve the documents attached to the Side Letter as Schedule C and Schedule D.  [* * *]. 
(d)[* * *].  
(e)[* * *].
(f)Expenses incurred [* * *] shall be considered Shared Commercial Expenses, as reflected in 2021 US Budget.
(g)In accordance with the terms of the LCA, on an annual basis, (a) the Global Commercialization Plan (including the corresponding Global Commercialization Budget) for Dupilumab may be updated jointly by the Parties via the JCC and approved by the JSC, and (b) each Country/Region Commercialization Plan (including the corresponding Country/Region Commercialization Budget) for Dupilumab may be updated jointly by the Parties via the applicable Country/Region Commercialization Committee and approved by the JCC.  Performance of marketing tactics in the United States shall be shared by the Parties, in accordance with the relevant Plans; provided that, the Party performing any such marketing tactic must comply with Law, the terms of the LCA, and the applicable Plan (including the corresponding budget) as approved in accordance with the terms of the LCA.
2.4.    Dupilumab Global HQ FTEs.  [* * *].  Such allocation of Dupilumab Global HQ FTEs shall be referred to as the “Global HQ FTE Allocation”.
3.Acknowledgements and Agreements with respect to 2020 Manufacturing Costs.  The Parties acknowledge and agree that [* * *].
4.Acknowledgements and Agreements with respect to Timing of Approval of Global Commercialization Plans and Country/Region Commercialization Plans. 
4.1.    Section 6.2 of the LCA is hereby amended by deleting the fourth sentence of such section and replacing it with the following:  “Such Global Commercialization Plan for each subsequent Contract Year shall be updated by the JCC and approved by the JSC prior to [* * *].”
4.2.    Section 6.3 of the LCA is hereby amended by deleting the third sentence of such section and replacing it with the following:  “Such Country/Region Commercialization Plan for each subsequent Contract Year shall be updated by the applicable Country/Region Commercialization Committee, and approved by the JCC, prior to [* * *].”
4

5.Miscellaneous Provisions
5.1.    Due Organization, Valid Existence and Due Authorization.  Each Party represents and warrants to the other Party, as of the Effective Date, as follows:  (a) it is duly organized and validly existing under the Laws of its jurisdiction of incorporation; (b) it has full corporate power and authority and has taken all corporate action necessary to enter into this Fourth Amendment; (c) the execution of this Fourth Amendment will not constitute a breach of, or conflict with, its organizational documents or any other agreement by which it is bound or requirement of applicable Laws or regulations; and (d) this Fourth Amendment is its legal, valid and binding obligation, enforceable in accordance with the terms and conditions hereof (subject to applicable Laws of bankruptcy and moratorium). 
5.2.    Miscellaneous.  The provisions of Sections 20.1, 20.3, 20.5, 20.6, 20.7, 20.8, 20.11, 20.12 and 20.17 of the LCA shall apply mutatis mutandis to this Fourth Amendment as though set out in full in this Fourth Amendment.
5.3.    No Other Amendments.  Except as expressly amended hereby, all of the terms and conditions of the LCA shall remain in full force and effect.
[Signature Page Follows]
5

IN WITNESS WHEREOF, Sanofi and Regeneron have caused this Fourth Amendment to be executed by their duly authorized representatives as of the Execution Date.

SANOFI BIOTECHNOLOGY SAS

By    /s/ Alban de La Sablière        
Name:  Alban de La Sablière
Title:  President

SANOFI

By    /s/ Alban de La Sablière        
    Name:  Alban de La Sablière
Title:  Head of Sanofi Partnering, SVP

REGENERON PHARMACEUTICALS, INC.

By    /s/ Kerry Reinertsen            
    Name: Kerry K. Reinertsen, Ph.D.
    Title: Senior Vice President, Strategic Alliances
[Signature Page to Fourth Amendment to Amended and Restated License and Collaboration Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]